Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Merck Animal Health's expansion ...
Merck & Co., Inc. (NYSE: MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection ...
Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 12th Edition of their annual conference, "Merck Foundation Africa Asia Luminary", in partnership with the Government of The ...
LONDON & SAN FRANCISCO-- (BUSINESS WIRE)--December 16, 2025-- ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...
ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its ...
Pregnant people who received a COVID-19 vaccine were far less likely to experience severe illness or deliver their babies prematurely, according to a major new UBC-led study published in JAMA. Drawing ...
Cyclingnews on MSN
'I want to try to be the best athlete Belgium has ever known' – Remco Evenepoel inspired by Eddy Merckx after fifth Sportsman of the Year award
Remco Evenepoel was named as the Belgian Sportsman of the Year for a fifth consecutive time on Sunday, with Eddy Merckx's ...
Early and sustained ctDNA clearance in early breast cancer treated with neoadjuvant HER2-targeted therapy tracks closely with pathologic complete response to treatment and 3-year outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback